Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies underwa ...

You have two major options when you’re struggling with something: wallow in it or try to look on the bright side. Turns out, ...

Research in older adults diagnosed with rheumatic and musculoskeletal diseases (RMDs) comes with unique challenges, as these patients often face consequences of ageing, such as multimorbidity, ...

What does it mean for a computer to think like a doctor? This question has vexed physicians working on clinical reasoning artificial intelligence (AI) for more than 70 years. The first generation of ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

Clinical laboratories still face uncertainty and the difficult decision of whether to start the work needed to comply with ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

Time costs, often overlooked in health care, create economic burdens for patients and caregivers, impacting income and ...

An innovative lifestyle intervention called Super Rehab, which has been trialled at the Royal United Hospitals Bath NHS Foundation Trust, has been praised for helping to halt the progression of heart ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

It is rated on a 2026 PE ratio of 10 even though the integration of bolt-on acquisitions will help drive future growth ...